| 17.77 0.68 (3.98%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.79 | 1-year : | 25.45 |
| Resists | First : | 18.65 | Second : | 21.79 |
| Pivot price | 16.46 |
|||
| Supports | First : | 15.67 | Second : | 13.82 |
| MAs | MA(5) : | 17.55 |
MA(20) : | 16.14 |
| MA(100) : | 16.03 |
MA(250) : | 17.16 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 76.1 |
D(3) : | 76.9 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 25 | Low : | 13.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PLSE ] has closed below upper band by 24.8%. Bollinger Bands are 110.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.14 - 18.24 | 18.24 - 18.33 |
| Low: | 16.84 - 16.97 | 16.97 - 17.09 |
| Close: | 17.58 - 17.77 | 17.77 - 17.95 |
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Fri, 26 Sep 2025
Pulse Biosciences (NASDAQ:PLSE) Shares Up 6.3% - Should You Buy? - MarketBeat
Wed, 24 Sep 2025
17,800 Shares in Pulse Biosciences, Inc $PLSE Purchased by Strs Ohio - MarketBeat
Mon, 22 Sep 2025
Pulse Biosciences (NASDAQ:PLSE) Shares Up 9.8% - Still a Buy? - MarketBeat
Wed, 17 Sep 2025
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sat, 13 Sep 2025
Pulse Biosciences Stock (PLSE) Opinions on FDA IDE Approval - Quiver Quantitative
Fri, 12 Sep 2025
Pulse Biosciences (PLSE) director Duggan buys shares worth $2.79 million - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 67 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 74.2 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 2,500 (K) |
| Shares Short P.Month | 2,450 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56.2 % |
| Return on Equity (ttm) | -103.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -16.46 |
| PEG Ratio | 0 |
| Price to Book value | 11.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -26.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|